Neutralizing possibilities of whole virion and mRNA vaccine triggered antibodies of Wuhan strain of SARS-CoV-2 with receptor binding domains of spike proteins of Delta and Omicron strains  

作　　者：Shilpa Barthwal Bennet Angel Annette Angel Vinod Joshi BM Shareef Nuzhat M Peer Poorna Khaneja Ambreen S Khan Bhawna Sharma Neha Singh Ramesh Joshi Komal Tomar Kiran Yadav Satendra P Singh 

机构地区：[1]Advance Centre for Virology&Immunology,Sharda University,Greater Noida,U.P.,201310,India [2]Sharda School of Agricultural Sciences,Sharda University,Greater Noida,U.P.,201310,India [3]Department of Microbiology,School of Medical Sciences&Research,Sharda Hospital,Greater Noida,U.P.,201310,India

出　　处：《Asian Pacific Journal of Tropical Medicine》2023年第2期92-94,I0008,共4页亚太热带医药杂志（英文版）

基　　金：funded by Indian Council of Medical Research,Grant Number 2021-6369.

摘　　要：Mutations in the receptor binding domain(RBD)of SARS-CoV-2 spike protein have given birth to the new variants of concern viz.Delta and Omicron strain.As we are using vaccines which are either mRNA of spike protein of Wuhan strain or its whole virion vaccine,these vaccines will trigger antibodies to be able to bind with the epitopes of spike protein of Wuhan strain.There appears a need to study whether vaccine generated circulating neutralizing antibodies in vaccinated people are able to neutralize the receptor binding domain of spike protein of currently circulating Delta and Omicron strains as well.We need to address this contention in two phases:first to undertake docking studies of vaccine generated antibodies with Wuhan,Delta and Omicron strains and second to conduct the wet lab studies and observe antigen-antibody bindings employing Immunofluorescence and Cryo-Electron Microscopic studies.The present paper reports results of docking studies using bioinformatic softwares to provide the baseline information for wet lab studies.

关 键 词：VACCINE ANTIBODIES neutral 

分 类 号：R563.1[医药卫生—呼吸系统]